Vascular Biogenics Ltd (VBLT) is a late stage biopharmaceutical company, developing treatments for cancer and immune-inflammatory diseases. It was founded in Israel since 2000. And came public in the second half of 2014. The firm has a market capitalization of approximately $140 million. The stock is currently selling at around $5.25 a share with a 52 week high of approximately $8.50 a share.
The company’s focus addresses clear needs in the cancer and immune-inflammatory disease markets which represent the potential for billions in annual revenues in the US and Europe. With a key fast tracked/orphan status Phase III trial expected to provide interim results in the first half of 2017, this concern merits a closer look.